Almirall brings out the budget ax, plans to chop 250 staffers;

@FierceBiotech: I-SPY a controversy over Puma's positive PhII test of neratini. Story | Follow @FierceBiotech

@JohnCFierce: My favorite dysfunctional pharma company, Eli Lilly, reports yet another PhIII flop. Release | Follow @JohnCFierce

@DamianFierce: If Transcept can't find a buyer, it's going to liquidate come Q2. Release | Follow @DamianFierce

@EmilyMFierce: Cellular Dynamics and Jain Foundation partner on stem cell models for muscular dystrophy. News | Follow @EmilyMFierce

> Spain's Almirall says it will lay off 250 staffers as part of a widespread effort to cut costs in Europe. No details were provided on who will get pink slips, or which departments are most heavily affected. "We have been investing heavily over the last few years to maximize the potential of our portfolio of new products, says CEO Eduardo Sanchiz. "However these efforts are happening at a time of unprecedented challenges in our industry and in key markets for our company. We have growth opportunities ahead of us and we will only manage to achieve them if we rebalance our resources and focus our efforts there where we are in a better position to realize long term success." Release

> Albuquerque, NM-based Tyrosine Pharma named Wayne Laslie as its new CEO. The biotech is developing a new stroke treatment. Release

Medical Device News

@FierceMedDev: That didn't take long: Myriad Genetics targets LabCorp with BRCA patent suit. Item | Follow @FierceMedDev

@MarkHFierce: DioGenix pulled in $3.2M in private financing to fuel continued work on its MS diagnostic test. Release | Follow @MarkHFierce

@MichaelGFierce: BioDelivery Sciences is moving ahead on its #diabetes pain gel with the FDA's blessing. Story | Follow @MichaelGFierce

@GalenMoore: BofA: neratinib likely to do well in trials as an adjuvant & 3rd line for metastatic breast cancer. Note via @bradloncar | Follow @GalenMoore

> Medtronic's new version of Symplicity gets a green light in EU and Australia. News

> Cardiac stents fall short versus surgery, drugs in 2 new JAMA studies. More

Pharma News

@FiercePharma: GSK fends off wrongful death case alleging Paxil led to abortion. News | Follow @FiercePharma

@EricPFierce: Mylan intends to launch 800 injectable products in next 5 years--150 in U.S.--now that it owns Agila. Story | Follow @EricPFierce

@CarlyHFierce: SEC: Provenge critic lied about her bets Dendreon stock would fall. Yesterday's story | Follow @CarlyHFierce

> Sanofi's MS drug Lemtrada tripped up again, this time in U.K. More

> Pfizer fights Hanmi in Korea over its Viagra design. Story

Vaccines News

> The argument for vaccinating: 100M cases of disease prevented in U.S. Story

> A California nonprofit is crowdfunding its tech-enabled HIV vaccine project. Piece

> Whooping cough vaccine fails to stop the disease's spread in FDA animal study. More

> TB vaccine shows promise in preventing MS. News

> CDC considers expanding the use of Bexsero as meningitis outbreak spreads. Article

> PaxVax raises $22M for PhIII trial of cholera vaccine. Item

Pharma Manufacturing News

> In cancer immunotherapy joint venture, Fred Hutch and MSKCC face manufacturing challenges. Piece

> Pfizer is whacking 150 jobs in closure of Irish packaging plant. News

> FDA warning letter tasks Wockhardt with global plant assessment. More

> PhRMA begins another lawsuit against a drug-disposal law. Story

> Boehringer taps BofA to talk up potential of sterile injectables plant. Article

> Patheon invests in U.K. plant, posts operating loss. Item

 

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.